Takeaways: The C-POST data – 68% reduction in recurrence or death versus placebo – gives Regeneron a strong clinical story to push Libtayo earlier in the treatment pathway,...
Takeaways: The decision should expand use of Keytruda plus enfortumab vedotin in the perioperative setting by giving oncologists a data-backed option that improves event-free...
Takeaways: Septa’s acquisition of CeeNU from Bristol Myers Squibb turns it into a supply‑critical oncology player in Canada, securing an essential chemotherapy that has faced...
Takeaways: The Canadian approval of Besremi gives PharmaEssentia a new, targeted therapy in the chronic myeloproliferative neoplasm space, expanding its hematology/oncology footprint beyond Taiw...
Takeaways: This approval expands Padcev from later-line urothelial cancer into earlier-stage muscle-invasive bladder cancer, which should broaden Pfizer’s addressable market in Canada and streng...
Takeaways: Roche’s pCPA win for Itovebi is a major reimbursement de-risking event in Canada, because it moves the drug much closer to broad public coverage after a ...
Takeaways: Shortening Breyanzi’s required stay-near-centre period and driving ban lowers the logistical and financial barriers to CAR T, which should modestly expand the eligible treat...
Takeaways: Roche’s dual-formulation (IV and SC) authorization for Lunsumio (mosunetuzumab) in Canada creates flexible, fixed-duration access for relapsed/refractory follicular lymphoma...
